SGLT2 Inhibitors and Cardiovascular Outcomes: Do They Differ or There is a Class Effect? New Insights from the EMPA-REG OUTCOME trial and the CVD-REAL Study-Reference-Cited by-同舟云学术

SGLT2 Inhibitors and Cardiovascular Outcomes: Do They Differ or There is a Class Effect? New Insights from the EMPA-REG OUTCOME trial and the CVD-REAL Study

Published:2021-07 Issue:4 Volume:16 Page:258-265
ISSN:1573-403X
Container-title:Current Cardiology Reviews
language:en
Short-container-title:CCR

Author:

Kyriakos Georgios¹,Quiles-Sanchez Lourdes V.²,Garmpi Anna³,Farmaki Paraskevi⁴^ORCID,Kyre Konstantina⁵,Savvanis Spyridon⁶,Antoniou Vasileios K.⁷,Memi Eleni⁸

Affiliation:

1. Seccion de Endocrinologia y Nutrition, Hospital General Universitario Santa Lucia, Cartagena, Spain

2. Centro de Salud Jesús Marín, Murcia, Spain

3. Department of Internal Medicine, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece

4. 1st Department of Pediatrics, “Aghia Sophia Children’s Hospital” Medical School, National and Kapodistrian University of Athens, Athens, Greece

5. Internal Medicine Department, KAT General Hospital, Athens, Greece

6. Department of Internal Medicine General Hospital of Athens "Elpis", Athens, Greece

7. Breast Surgical Clinic, Saint Savvas Anti-Cancer Hospital, Athens, Greece

8. Unit of Endocrinology, Diabetes Mellitus and Metabolism, Aretaieion University Hospital, Medical School of Athens, Ethnikon and Kapodistrian University of Athens, Athens, Greece

Abstract

A new group of hypoglycemic drugs has been used to treat diabetes type 2. This group is active sodium glucose co-transporter (SGLT2) or SGLT2 inhibitors. It has been shown that besides the treatment of diabetes, this drug class is responsible for the mildness of the cardiovascular events shown in patients with diabetes type 2. However, there is an intriguing question regarding the range of SGLT2 inhibitors and if there is a difference between them or if there is a class effect among their results. EMPA-REG OUTCOME trial and the CVD-study are used to answer this question. Additional information from the DECLARE-TIMI 58 and Dapa-HF trials is studied.

Publisher

Bentham Science Publishers Ltd.

Subject

Cardiology and Cardiovascular Medicine,General Medicine

Reference34 articles.

1. Soares I.; Carneiro A.V.; Drug class effects: Definitions and practical applications. Rev Port Cardiol 2002,21(9),1031-1042

2. Chao E.C.; Henry R.R.; SGLT2 inhibition--a novel strategy for diabetes treatment. Nat Rev Drug Discov 2010,9(7),551-559

3. Tancredi M.; Rosengren A.; Svensson A.M.; Excess mortality among persons with type 2 diabetes. N Engl J Med 2015,373(18),1720-1732

4. Valentine V.; The role of the kidney and sodium-glucose cotransporter-2 inhibition in diabetes management. Clin Diabetes 2012,30(4),151-155

5. Abdul-Ghani M.; Del Prato S.; Chilton R.; DeFronzo R.A.; SGLT2 inhibitors and cardiovascular risk: Lessons learned from the EMPA-REG OUTCOME study. Diabetes Care 2016,39(5),717-725

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Atrial fibrillation in cancer, anticancer therapies, and underlying mechanisms;Journal of Molecular and Cellular Cardiology;2024-09

2. Predictive value of combined triglyceride-glucose index and glycated hemoglobin for long-term cardiovascular outcomes in stable coronary artery disease;2024-01-25

3. Association Between Use of Sodium-Glucose Cotransporter-2 Inhibitors or Angiotensin Receptor-Neprilysin Inhibitor and the Risk of Atherosclerotic Cardiovascular Disease With Coexisting Diabetes and Heart Failure;Journal of Cardiovascular Pharmacology and Therapeutics;2024-01

4. Traditional Therapeutics and Potential Epidrugs for CVD: Why Not Both?;Life;2023-12-22

5. mTORC1 and SGLT2 Inhibitors—A Therapeutic Perspective for Diabetic Cardiomyopathy;International Journal of Molecular Sciences;2023-10-11